Healio Minute, Breast Cancer Edition: Top Headlines for the Week of October 3, 2022
In this episode, FDA approves Rolvedon to reduce infection incidence; women want more education on sexual health during treatment; abemaciclib regimen shows further signs of benefit and more.
Read the full coverage here:
FDA approves Rolvedon to reduce infection incidence when taking certain anticancer drugs
Women with breast cancer want more education on sexual health during treatment
Abemaciclib regimen shows further signs of benefit in advanced breast cancer subgroup
Cancer-related fatigue may impact balance after breast cancer treatment
Chronic inflammation linked to cognitive difficulties among older breast cancer survivors
References:
Carroll JE, et al. J Clin Oncol. 2022;doi:10.1200/JCO.22.00406.
Goetz MP, et al. Abstract LBA15. Presented at: European Society for Medical Oncology Congress. Sept. 9-13, 2022; Paris.
Huynh V, et al. Ann Surg Oncol. 2022;doi:10.1245/s10434-022-12126-7.
Wechsler S, et al. Rehab Oncol. 2022;doi:10.1097/01.REO.0000000000000308.
Collapse
